<?xml version="1.0" encoding="UTF-8"?>
<p>A growing concern regards the development of critical illness neuropathy and critical illness myopathy in patients with severe SARS-CoV-2 infection requiring mechanical ventilation. The use of non-depolarising neuromuscular blocking agents is associated with an increased risk of critical illness neuropathy/critical illness myopathy and should be administered with caution.
 <sup>
  <xref rid="r113" ref-type="bibr">113</xref>
 </sup> Disuse atrophy and resultant weakness due to damage to type 2 muscle fibres are common in patients bedridden for prolonged periods, and could be worrisome for neurologists in the coming days.
 <sup>
  <xref rid="r113" ref-type="bibr">113</xref>
 </sup>
</p>
